摘要
目的观察不同剂量多巴丝肼(美多芭)增效治疗难治性抑郁症(TRD)的疗效与药物副反应。方法TRD患者90例随机分为了组,在原有治疗方案基础上分别增加多巴丝肝250 mg/d,375 mg/d,500 mg/d口服治疗。在入组前、以及干预后第2、4、8、24、48周末5个访视点进行汉密尔顿抑郁量表(HAMD-17)和药物不良反应评定量表(TESS)评估。比较3组间疗效与不良反应的差异。以及各组治疗效果与治疗时间的关系。结果治疗前3组HAMID-17评分比较差异无统计学意义,随着治疗时间的延长,各组有效率与缓解率均呈现.上升趋势,其中375 mg/d组与500 mg/d组上升速度更明显。3组不良反应的发生率差异无统计学意义。以治疗24周有效为结局变量,单因素分析显示治疗分组、病程、家族史为治疗效果的可能影响因素。多元回归分析显示,375 mg/d治疗组效果明显优于250 mg/d治疗组。结论关多芭作为增效剂治疗TRD有较好的效果,其中美多芭375 mg/d为最优治疗剂量,24周以上为最佳治疗时间。
Objective To observe the efBcacy and side effects of difierent doses of Madopar synergism in the treatment of refractory depression.Methods 90 patients with refractory depression were randomly divided into three groups by randomized controlled single-blind clinical trial design.On the basis of the original treatment plan,250 mg/d,375 mg/d,500 mg/d of Madopar were added.At the 2nd,4 th,8th,24th and 48th weekend,5 viewpoints were used to evaluate the curative effect and adverse reactions.Results There was no significant difierence between HAMA and HAMD scores in the three groups before treatment.With the prolongation of treatment time,the effective rate of each group showed an upward trend,among which 375 mg/d group and 500 group increased more significantly.Treatment group,course of disease and family history were the possible influencing factors of treatment effect after 24 weeks.Conclusion Madopar 375 mg/d group was the best treatment dose and 24 weeks or more was the best treatment time.
出处
《浙江临床医学》
2021年第9期1312-1314,1318,共4页
Zhejiang Clinical Medical Journal
基金
浙江省金华市科技计划项目(2018-4482)。
关键词
难治性抑郁症
增效剂
多巴丝肼
Refractory depression
Synergist
Levodopa and benserazide hydrochloride
